Highlights of the 2025 American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia
Heart disease, including atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death worldwide.1 In the U.S. alone, almost 700 000 people died from heart disease in 2021.2 In addition to hypertension, diabetes, obesity, smoking, and elevated levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides are associated with metabolic syndrome and heart disease.1 Recognizing the important role of endocrinologists and the endocrine care team, the American Association of Clinical Endocrinology (AACE) prioritized an update of the 2017 dyslipidemia guideline using the newly adopted Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodological framework.
